

April 28, 2022-

## Kyoto Drug Discovery & Development successfully concludes a pre-IND meeting with FDA

Kyoto Drug Discovery & Development successfully completed a pre-IND meeting with the US Food and Drug Administration (FDA) for the KUS121 under development for the treatment of central retinal artery occlusion (CRAO).

CRAO is a serious disease called "myocardial infarction of the eye", in which the central retinal artery is occluded by a thrombus, resulting in rapid and often irreversible visual impairment and visual impairment. Currently, there is no standard treatment, so patients are only having eye massage, fibrinolytic system treatment, intraocular pressure drop treatment, vasodilation treatment, hyperbaric oxygen therapy, etc.

KUS121 suppresses ischemia-reperfusion injury of retinal cells and strongly protects cells. It is expected as the standard and only effective treatment for CRAO. We are actively developing for Phase II trials in the United States.

Dr. Kunihiro Musashi, an ophthalmologist and our CEO, mentioned "CRAO is still one of the incurable diseases. We will continue to develop KUS121 so that it can become the breakthrough saver of patients around the world. It is a big step for our wish to successfully complete the pre-IND meeting with the FDA."